June 15, 2020 / 1:44 PM / a month ago

BRIEF-Adamis Pharmaceuticals Announces License To Commercialize Tempol

June 15 (Reuters) - Adamis Pharmaceuticals Corp:

* ADAMIS PHARMACEUTICALS ANNOUNCES LICENSE TO COMMERCIALIZE TEMPOL, A NOVEL INVESTIGATIONAL ANTI-INFLAMMATORY AND ANTIOXIDANT DRUG FOR THE TREATMENT OF RESPIRATORY DISEASES INCLUDING COVID-19

* ADAMIS PHARMACEUTICALS - EXCLUSIVE LICENSE INCLUDES USE OF TEMPOL FOR REDUCING RADIATION DERMATITIS IN PATIENTS UNDERGOING TREATMENT FOR CANCER

* ADAMIS PHARMACEUTICALS - UNDER AGREEMENT WITH MATRIX, IF ANY PRODUCTS ARE COMMERCIALIZED, NET PROFITS WILL BE EQUALLY DISTRIBUTED BETWEEN PARTIES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below